Vaxart Financials
| VXRT Stock | USD 0.52 0.02 4.00% |
Vaxart |
Please note, the imprecision that can be found in Vaxart's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxart Inc. Check Vaxart's Beneish M Score to see the likelihood of Vaxart's management manipulating its earnings.
Vaxart Stock Summary
Vaxart competes with Inovio Pharmaceuticals, Ibio, Co Diagnostics, Novavax, and Ocugen. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US92243A2006 |
| CUSIP | 92243A200 090694100 053761102 629519109 628716102 656755105 |
| Location | California; U.S.A |
| Business Address | 170 Harbor Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | vaxart.com |
| Phone | 650 550 3500 |
| Currency | USD - US Dollar |
Vaxart Key Financial Ratios
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.33 | ||||
| Target Price | 4.83 | ||||
| Number Of Employees | 109 | ||||
| Beta | 0.82 |
Vaxart Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vaxart's current stock value. Our valuation model uses many indicators to compare Vaxart value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vaxart competition to find correlations between indicators driving Vaxart's intrinsic value. More Info.Vaxart Inc is rated fourth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Vaxart by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vaxart Inc Systematic Risk
Vaxart's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vaxart volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Vaxart Inc correlated with the market. If Beta is less than 0 Vaxart generally moves in the opposite direction as compared to the market. If Vaxart Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vaxart Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vaxart is generally in the same direction as the market. If Beta > 1 Vaxart moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Vaxart is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Vaxart has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Vaxart's financials are consistent with your investment objective using the following steps:- Review Vaxart's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Vaxart's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Vaxart's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Vaxart's stock is overvalued or undervalued.
Vaxart February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vaxart help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vaxart Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vaxart Inc based on widely used predictive technical indicators. In general, we focus on analyzing Vaxart Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vaxart's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.85 | |||
| Information Ratio | 0.0019 | |||
| Maximum Drawdown | 49.25 | |||
| Value At Risk | (8.47) | |||
| Potential Upside | 11.9 |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.